Screener
Corvus Pharmaceuticals CRVS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Loss from equity method investment | (599) | (539) |
| Net (loss) income | $(13,692) | $15,193 |
| Net (loss) income per share, basic | $(0.15) | $0.21 |
| Net loss per share, diluted | $(0.15) | $(0.13) |
| Shares used to compute net (loss) income per share, basic | 89,996,728 | 72,126,496 |
| Shares used to compute net loss per share, diluted | 89,996,728 | 75,152,514 |
| Other comprehensive (loss) income: | ||
| Unrealized loss on marketable securities | (334) | (23) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's EPS (diluted)?
- Corvus Pharmaceuticals (CRVS) reported EPS (diluted) of -$0.15 in Q1 2026.
- How has Corvus Pharmaceuticals's EPS (diluted) changed year-over-year?
- Corvus Pharmaceuticals's EPS (diluted) decreased by 15.4% year-over-year, from -$0.13 to -$0.15.
- What is the long-term trend for Corvus Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's EPS (diluted) has grown at a -17.1% compound annual growth rate (CAGR), from -$1.06 to -$0.50.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Corvus Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude